2018
A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma
Weber JS, Sznol M, Sullivan RJ, Blackmon S, Boland G, Kluger HM, Halaban R, Bacchiocchi A, Ascierto PA, Capone M, Oliveira C, Meyer K, Grigorieva J, Asmellash SG, Roder J, Roder H. A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma. Cancer Immunology Research 2018, 6: 79-86. PMID: 29208646, DOI: 10.1158/2326-6066.cir-17-0412.Peer-Reviewed Original ResearchConceptsAcute phase reactantsCheckpoint inhibitorsOverall survivalPhase reactantsIpilimumab-treated patientsPD-1 blockadeTrials of nivolumabBetter overall survivalIndependent patient cohortsPretreatment serumPD-1Melanoma patientsValidation cohortMetastatic melanomaMultipeptide vaccinePatient cohortPooled analysisWorse outcomesClinical dataPatientsMultivariate analysisComplement cascadeMass spectrometry analysisNivolumabCohort
1996
Growth Regulatory Proteins that Repress Differentiation Markers in Melanocytes Also Downregulate the Transcription Factor Microphthalmia
Halaban R, Böhm M, Dotto P, Moellmann G, Cheng E, Zhang Y. Growth Regulatory Proteins that Repress Differentiation Markers in Melanocytes Also Downregulate the Transcription Factor Microphthalmia. Journal Of Investigative Dermatology 1996, 106: 1266-1272. PMID: 8752668, DOI: 10.1111/1523-1747.ep12348972.Peer-Reviewed Original ResearchConceptsTranscription factorsFibroblast growth factorBasic fibroblast growth factorMelanocyte-specific genesMelanogenic gene expressionTranscription factor microphthalmiaDownregulated transcription factorsDNA consensus siteTyrosinase-related protein 1Human metastatic melanoma cellsImmortalized mouse melanocytesPink-eyed dilutionCloudman S91 mouse melanomaMetastatic melanoma cellsSequestration of p300Transcriptional adaptorGrowth factorE1A mutantsConsensus sitesMouse melanocytesRegulatory proteinsMolecular basisOncogene RasGene expressionTumorigenic transformation